|
1
|
Gramatzki D, Dehler S, Rushing EJ, Zaugg
K, Hofer S, Yonekawa Y, Bertalanffy H, Valavanis A, Korol D,
Rohrmann S, et al: Glioblastoma in the Canton of Zurich,
Switzerland revisited: 2005 to 2009. Cancer. Apr 18–2016.(Epub
ahead of print). View Article : Google Scholar
|
|
2
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Weller M, van den Bent M, Hopkins K, Tonn
JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D,
Henriksson R, Balana C, et al: EANO guideline for the diagnosis and
treatment of anaplastic gliomas and glioblastoma. Lancet Oncol.
15:e395–e403. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huse JT and Holland EC: Targeting brain
cancer: Advances in the molecular pathology of malignant glioma and
medulloblastoma. Nat Rev Cancer. 10:319–331. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Charles NA, Holland EC, Gilbertson R,
Glass R and Kettenmann H: The brain tumor microenvironment. Glia.
59:1169–1180. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lin Y, Zhang G, Zhang J, Gao G, Li M, Chen
Y, Wang J, Li G, Song SW, Qiu X, et al: A panel of four cytokines
predicts the prognosis of patients with malignant gliomas. J
Neurooncol. 114:199–208. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Prosniak M, Harshyne LA, Andrews DW,
Kenyon LC, Bedelbaeva K, Apanasovich TV, Heber-Katz E, Curtis MT,
Cotzia P and Hooper DC: Glioma grade is associated with the
accumulation and activity of cells bearing M2 monocyte markers.
Clin Cancer Res. 19:3776–3786. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yeung YT, McDonald KL, Grewal T and Munoz
L: Interleukins in glioblastoma pathophysiology: Implications for
therapy. Br J Pharmacol. 168:591–606. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhu VF, Yang J, Lebrun DG and Li M:
Understanding the role of cytokines in glioblastoma multiforme
pathogenesis. Cancer Lett. 316:139–150. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schiering C, Krausgruber T, Chomka A,
Fröhlich A, Adelmann K, Wohlfert EA, Pott J, Griseri T, Bollrath J,
Hegazy AN, et al: The alarmin IL-33 promotes regulatory T-cell
function in the intestine. Nature. 513:564–568. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Beltrán CJ, Núñez LE, Díaz-Jiménez D,
Farfan N, Candia E, Heine C, López F, González MJ, Quera R and
Hermoso MA: Characterization of the novel ST2/IL-33 system in
patients with inflammatory bowel disease. Inflamm Bowel Dis.
16:1097–1107. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Palmer G and Gabay C: Interleukin-33
biology with potential insights into human diseases. Nat Rev
Rheumatol. 7:321–329. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Préfontaine D, Nadigel J, Chouiali F,
Audusseau S, Semlali A, Chakir J, Martin JG and Hamid Q: Increased
IL-33 expression by epithelial cells in bronchial asthma. J Allergy
Clin Immunol. 125:752–754. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Byers DE, Alexander-Brett J, Patel AC,
Agapov E, Dang-Vu G, Jin X, Wu K, You Y, Alevy Y, Girard JP, et al:
Long-term IL-33-producing epithelial progenitor cells in chronic
obstructive lung disease. J Clin Invest. 123:3967–3982. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kempf W, Zollinger T, Sachs M, Ullmer E,
Cathomas G, Dirnhofer S and Mertz KD: Granulomas are a source of
interleukin-33 expression in pulmonary and extrapulmonary
sarcoidosis. Hum Pathol. 45:2202–2210. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Moulin D, Donzé O, Talabot-Ayer D, Mézin
F, Palmer G and Gabay C: Interleukin (IL)-33 induces the release of
pro-inflammatory mediators by mast cells. Cytokine. 40:216–225.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schmitz J, Owyang A, Oldham E, Song Y,
Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, et
al: IL-33, an interleukin-1-like cytokine that signals via the IL-1
receptor-related protein ST2 and induces T helper type 2-associated
cytokines. Immunity. 23:479–490. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chackerian AA, Oldham ER, Murphy EE,
Schmitz J, Pflanz S and Kastelein RA: IL-1 receptor accessory
protein and ST2 comprise the IL-33 receptor complex. J Immunol.
179:2551–2555. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Küchler AM, Pollheimer J, Balogh J,
Sponheim J, Manley L, Sorensen DR, De Angelis PM, Scott H and
Haraldsen G: Nuclear interleukin-33 is generally expressed in
resting endothelium but rapidly lost upon angiogenic or
proinflammatory activation. Am J Pathol. 173:1229–1242. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Moussion C, Ortega N and Girard JP: The
IL-1-like cytokine IL-33 is constitutively expressed in the nucleus
of endothelial cells and epithelial cells in vivo: A novel
‘alarmin’? PLoS One. 3:e33312008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Carriere V, Roussel L, Ortega N, Lacorre
DA, Americh L, Aguilar L, Bouche G and Girard JP: IL-33, the
IL-1-like cytokine ligand for ST2 receptor, is a
chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci
USA. 104:282–287. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Alves-Filho JC, Sônego F, Souto FO,
Freitas A, Verri WA Jr, Auxiliadora-Martins M, Basile-Filho A,
McKenzie AN, Xu D, Cunha FQ and Liew FY: Interleukin-33 attenuates
sepsis by enhancing neutrophil influx to the site of infection. Nat
Med. 16:708–712. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Haraldsen G, Balogh J, Pollheimer J,
Sponheim J and Küchler AM: Interleukin-33-cytokine of dual function
or novel alarmin? Trends Immunol. 30:227–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Roussel L, Erard M, Cayrol C and Girard
JP: Molecular mimicry between IL-33 and KSHV for attachment to
chromatin through the H2A-H2B acidic pocket. EMBO Rep. 9:1006–1012.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xiong Z, Thangavel R, Kempuraj D, Yang E,
Zaheer S and Zaheer A: Alzheimer's disease: Evidence for the
expression of interleukin-33 and its receptor ST2 in the brain. J
Alzheimers Dis. 40:297–308. 2014.PubMed/NCBI
|
|
26
|
Christophi GP, Gruber RC, Panos M,
Christophi RL, Jubelt B and Massa PT: Interleukin-33 upregulation
in peripheral leukocytes and CNS of multiple sclerosis patients.
Clin Immunol. 142:308–319. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yasuoka S, Kawanokuchi J, Parajuli B, Jin
S, Doi Y, Noda M, Sonobe Y, Takeuchi H, Mizuno T and Suzumura A:
Production and functions of IL-33 in the central nervous system.
Brain Res. 1385:8–17. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hudson CA, Christophi GP, Gruber RC,
Wilmore JR, Lawrence DA and Massa PT: Induction of IL-33 expression
and activity in central nervous system glia. J Leukoc Biol.
84:631–643. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Han P, Mi WL and Wang YQ: Research
progress on interleukin-33 and its roles in the central nervous
system. Neurosci Bull. 27:351–357. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kempuraj D, Khan MM, Thangavel R, Xiong Z,
Yang E and Zaheer A: Glia maturation factor induces interleukin-33
release from astrocytes: Implications for neurodegenerative
diseases. J Neuroimmune Pharmacol. 8:643–650. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sun P, Ben Q, Tu S, Dong W, Qi X and Wu Y:
Serum interleukin-33 levels in patients with gastric cancer. Dig
Dis Sci. 56:3596–3601. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bergis D, Kassis V, Ranglack A, Koeberle
V, Piiper A, Kronenberger B, Zeuzem S, Waidmann O and Radeke HH:
High serum levels of the interleukin-33 receptor soluble ST2 as a
negative prognostic factor in hepatocellular carcinoma. Transl
Oncol. 6:311–318. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hu LA, Fu Y, Zhang DN and Zhang J: Serum
IL-33 as a diagnostic and prognostic marker in non-small cell lung
cancer. Asian Pac J Cancer Prev. 14:2563–2566. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fang KM, Yang CS, Lin TC, Chan TC and
Tzeng SF: Induced interleukin-33 expression enhances the
tumorigenic activity of rat glioma cells. Neuro Oncol. 16:552–566.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Louis DN, Ohgaki H, Wiestler B and Cavenee
WK: WHO Classification of Tumours of the Central Nervous System.
IARC Press. Lyon: 2007.
|
|
36
|
Cancer Genome Atlas Research Network:
Comprehensive genomic characterization defines human glioblastoma
genes and core pathways. Nature. 455:1061–1068. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gravendeel LA, Kouwenhoven MC, Gevaert O,
de Rooi JJ, Stubbs AP, Duijm JE, Daemen A, Bleeker FE, Bralten LB,
Kloosterhof NK, et al: Intrinsic gene expression profiles of
gliomas are a better predictor of survival than histology. Cancer
Res. 69:9065–9072. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Singhal G, Jaehne EJ, Corrigan F, Toben C
and Baune BT: Inflammasomes in neuroinflammation and changes in
brain function: A focused review. Front Neurosci. 8:3152014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jovanovic IP, Pejnovic NN, Radosavljevic
GD, Arsenijevic NN and Lukic ML: IL-33/ST2 axis in innate and
acquired immunity to tumors. Oncoimmunology. 1:229–231. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Villarreal DO, Wise MC, Walters JN,
Reuschel EL, Choi MJ, Obeng-Adjei N, Yan J, Morrow MP and Weiner
DB: Alarmin IL-33 acts as an immunoadjuvant to enhance
antigen-specific tumor immunity. Cancer Res. 74:1789–1800. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gao K, Li X and Zhang L, Bai L, Dong W,
Gao K, Shi G, Xia X, Wu L and Zhang L: Transgenic expression of
IL-33 activates CD8(+) T cells and NK cells and inhibits tumor
growth and metastasis in mice. Cancer Lett. 335:463–471. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Curran CS and Bertics PJ: Eosinophils in
glioblastoma biology. J Neuroinflammation. 9:112012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hussain SF, Yang D, Suki D, Aldape K,
Grimm E and Heimberger AB: The role of human glioma-infiltrating
microglia/macrophages in mediating antitumor immune responses.
Neuro Oncol. 8:261–279. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dong H, Zhang X and Qian Y: Mast cells and
neuroinflammation. Med Sci Monit Basic Res. 20:200–206. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Skaper SD, Facci L and Giusti P: Mast
cells, glia and neuroinflammation: Partners in crime? Immunology.
141:314–327. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Merk BC, Owens JL, Lopes MB, Silva CM and
Hussaini IM: STAT6 expression in glioblastoma promotes invasive
growth. BMC Cancer. 11:1842011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Choi YS, Choi HJ, Min JK, Pyun BJ, Maeng
YS, Park H, Kim J, Kim YM and Kwon YG: Interleukin-33 induces
angiogenesis and vascular permeability through ST2/TRAF6-mediated
endothelial nitric oxide production. Blood. 114:3117–3126. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gadani SP, Walsh JT, Smirnov I, Zheng J
and Kipnis J: The glia-derived alarmin IL-33 orchestrates the
immune response and promotes recovery following CNS injury. Neuron.
85:703–709. 2015. View Article : Google Scholar : PubMed/NCBI
|
